Biora Therapeutics
Progenity, Inc.: A leading biotech firm innovating in precision medicine, molecular testing, and targeted therapies.
Founded
2010Progenity, Inc.: A leading biotech firm innovating in precision medicine, molecular testing, and targeted therapies.
Biora Therapeutics, originally known as Progenity, Inc., was founded with the mission to revolutionize precision medicine and therapeutic delivery. The company focuses on developing innovative molecular testing products and smart-pill technologies aimed at improving patient outcomes. Their core offerings include the NaviCap™ Targeted Oral Delivery Platform for treating gastrointestinal diseases and the BioJet™ Systemic Oral Delivery Platform designed for needle-free delivery of large molecules. Biora Therapeutics targets the biotechnology and healthcare markets, particularly in areas requiring advanced diagnostic and therapeutic solutions.
Notable affiliated individuals include key researchers and executives with extensive backgrounds in biotechnology and precision medicine. The company has attracted significant investment from leading venture capital firms and has achieved milestones such as the successful commercialization of multiple molecular testing products. Biora Therapeutics' impact is evident in its contributions to improving medical decision-making and patient care through advanced diagnostic tools and novel therapeutic delivery systems.
Companies similar to Biora Therapeutics include Biotheryx, ProThera Biologics, Provenance Biopharmaceuticals and Precision Biologics.
Biora Therapeutics was founded in 2010.
Biora Therapeutics' headquarters is located in San Diego, CA, US.
Biora Therapeutics' most recent funding round was for $50M (USD) in September 2023.
As of Sep 19, 2023, Biora Therapeutics has raised a total of $308.3M (USD).
Biora Therapeutics has 375 employees as of Feb 5, 2024.
Provenance Biopharmaceuticals
provenancebio.com
